Medical and surgical therapy for cardiac remodeling

被引:10
作者
Bozkurt, B [1 ]
机构
[1] Vet Affairs Med Ctr, Dept Med, Cardiol Sect, Houston, TX 77030 USA
关键词
D O I
10.1097/00001573-199905000-00002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ventricular remodeling refers to changes in ventricular geometry, volume, mass, and myocellular structure in response to myocardial injury or alteration in loading conditions. Although initially adaptive as a consequence of the initial damage to the myocardium, progressive ventricular remodeling is ultimately a maladaptive process that is associated with significant cardiovascular morbidity and mortality. Treatment with an aim to halt or reverse remodeling with mainly two classes of medications, angiotensin-converting enzyme inhibitors and beta-adrenergic blockers, has been shown to improve the long-term outcome. The role of pharmacologic and surgical therapy in remodeling is evolving and may have an important impact on the development of new directions of therapy for heart failure, myocardial infarction, and hypertension. Curr Opin Cardiol 1999, 14:196-205 (C) 1999 Lippincott Williams & Wilkins, Inc.
引用
收藏
页码:196 / 205
页数:10
相关论文
共 73 条
[1]   MYOCARDIAL-INFARCTION IN RATS - INFARCT SIZE, MYOCYTE HYPERTROPHY, AND CAPILLARY GROWTH [J].
ANVERSA, P ;
BEGHI, C ;
KIKKAWA, Y ;
OLIVETTI, G .
CIRCULATION RESEARCH, 1986, 58 (01) :26-37
[2]  
ANVERSA P, 1991, AM J CARDIOL, V68, pD7
[3]   Myocyte cell death and ventricular remodeling [J].
Anversa, P ;
Olivetti, G ;
Leri, A ;
Liu, Y ;
Kajstura, J .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1997, 6 (02) :169-176
[4]   Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? [J].
Ball, SG ;
Hall, AS .
AMERICAN HEART JOURNAL, 1996, 132 (01) :244-250
[5]  
Blaufarb Ira S., 1996, American Journal of Cardiology, V77, p8C, DOI 10.1016/S0002-9149(96)00183-X
[6]   EFFECTS OF CAPTOPRIL TREATMENT ON LEFT-VENTRICULAR REMODELING AND FUNCTION AFTER ANTERIOR MYOCARDIAL-INFARCTION - COMPARISON WITH DIGITALIS [J].
BONADUCE, D ;
PETRETTA, M ;
ARRICHIELLO, P ;
CONFORTI, G ;
MONTEMURRO, MV ;
ATTISANO, T ;
BIANCHI, V ;
MORGANO, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (04) :858-863
[7]   Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction [J].
Bonarjee, VVS ;
Carstensen, S ;
Caidahl, K ;
Nilsen, DWT ;
Edner, M ;
Lindvall, K ;
Snapinn, SM ;
Berning, J .
AMERICAN HEART JOURNAL, 1996, 132 (01) :71-77
[8]   Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats [J].
Bozkurt, B ;
Kribbs, SB ;
Clubb, FJ ;
Michael, LH ;
Didenko, VV ;
Hornsby, PJ ;
Seta, Y ;
Oral, H ;
Spinale, FG ;
Mann, DL .
CIRCULATION, 1998, 97 (14) :1382-1391
[9]   Ceftazidime and management of nosocomial infections - March 27, 1995 [J].
Charbonneau, P ;
Jarlier, V .
MEDECINE ET MALADIES INFECTIEUSES, 1995, 25 :3-5
[10]   REGULATION OF COLLAGEN DEGRADATION IN THE RAT MYOCARDIUM AFTER INFARCTION [J].
CLEUTJENS, JPM ;
KANDALA, JC ;
GUARDA, E ;
GUNTAKA, RV ;
WEBER, KT .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1995, 27 (06) :1281-1292